PBMs Report Ease in Demand for Hydroxychloroquine
Pharmacy benefit managers last month reported an easing of demand for the antimalarial drug hydroxychloroquine following a rapid surge spurred [...]
Valid Insight Report Explores Insights from Roundtable on Payer Engagement
A new report from Valid Insight explores key insights generated from a roundtable discussion on payer engagement. The white paper, [...]
Podcast Highlights ‘Buy and Bill’ Model in Oncology
Memorial Sloan Kettering Cancer Center's Dr. Aaron Mitchell in the latest Relentless Health Value podcast discusses the "buy and bill" [...]
OptumRx: Rising Orphan Drug Competition Could Lead to Lower Prices
Increased competition in the orphan drug market could ultimately help pull down prices, OptumRx suggests in a new report. According [...]
ACR Tapped as Imaging Partner for COVID-19 Registry
The Society of Clinical Care Medicine (SCCM) has chosen the American College of Radiology (ACR) to be the main imaging [...]
Report: HEOR Services Market Poised for Rapid Growth
The health economics and outcomes research (HEOR) services market is set to see "rapid growth" between 2020-2025, according to a [...]
NPC: ‘Ready, aim, fire’ Mentality Detrimental in Health Care
Having a "ready, aim, fire" mentality can prove harmful when sharing health care information, the National Pharmaceutical Council (NPC) writes [...]
Legislation Aims to Prevent Pharma From Price-gouging During Pandemic
Two new bipartisan bills introduced by House Democrats aim to prevent the pharmaceutical industry from engaging in price-gouging on COVID-19 [...]
Report Reveals Racial Disparities in COVID-19 Outcomes
New data released by the government on Monday suggests black Americans under Medicare were roughly four times more likely as [...]
‘Domestic Reference Pricing’ for COVID-19 Drugs?
While the Trump administration has in the past proposed international reference pricing for drug pricing in the U.S., a Health [...]
NPC Plans Webinar in Prices for COVID-19 Drugs
An upcoming webinar hosted by the National Pharmaceutical Council (NPC) will discuss a range of pricing-related issues for COVID-19 drugs. [...]
Hahn: Some COVID-19 Changes to Remain
Food and Drug Administration (FDA) Chief Stephen Hahn recently said some changes made to address COVID-19 will remain in place, [...]
Informa Pharma Intelligence Plans 24-Hour Webinar Series
Informa Pharma Intelligence is set to host a free, 24-hour interactive webinar series on the latest insights into COVID-19. The [...]
Blog Post Explores Novel Value Elements for Assessment of COVID-19 Drugs
A recent Health Affairs blog post suggests the inclusion of more novel value elements in the assessment of COVID-19 drugs [...]
ISPOR-FDA Summit Transitions to Virtual Event
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) announced that the joint ISPOR-FDA Summit 2020, set for Sept. 29, [...]
Cytel Offers On-Demand Access to Webinar on Synethic, External Control Arms
A new on-demand webinar from Cytel offers insights into synthetic and external control arms in clinical trials. The webinar features [...]
Opinion: Move Forward with Evidence-based Care as Foundation
Evidence-based care should be the bedrock of health care moving forward, the authors of a recent opinion piece published on [...]
Cytel Paper Offers Insight into Trial Recruitment Targets
A new white paper from Cytel offers insight into how recruitment targets are "met with sound starting assumptions and key [...]
How Can HEOR Boost Outcomes?
The health economics and outcomes research (HEOR) framework can help facilitate more robust decision-making using "powerful data and insights," ISPOR [...]
Blog Post Touts VA, ICER Partnership as ‘Highly Beneficial’
The partnership between the Department of Veterans Affairs (VA) and the Institute for Clinical and Economic Review (ICER) has provided [...]
Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic [...]
Study Suggests Pfizer’s Vyndaqel is Too Expensive
A recent study published in JAMA Cardiology suggests the price tag on Pfizer's Vyndaqel is too high. According to a [...]
Sarepta Therapeutics’ Berry Talks Access to Rare Disease Treatments
Sarepta Therapeutics' Diane Berry in a recent Patients Rising Podcast discussed access to treatments for rare diseases. Berry is Sarepta [...]
ICER to Review Most Significant Drug Price Hikes
The Institute for Clinical and Economic Review (ICER) is set to review whether the most significant drug price increases are [...]
Study: Almost 9 in 10 Concerned about High Drug Prices Due to COVID-19
Almost nine in 10 adults in the U.S. are either "very" (55 percent) or "somewhat" (33 percent) concerned pharma will [...]